Literature DB >> 8799528

CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine.

J A Carrillo1, J Benitez.   

Abstract

We have investigated several factors that might be related to the occurrence of toxic effects during the performance of a urinary test with caffeine (300 mg p.o.), in 120 healthy volunteers. A total of 218 toxic effects were self-reported by eighty-two (68%) subjects. Females and nonsmokers were at the highest risk (chi-square test, P = 0.01). Furthermore, two nonsmoking females experienced a symptomatology with delirium, restlessness, muscle tremor, vomiting and wakefulness. Among females and nonsmokers, those subjects who experienced toxic effects had lower caffeine N3-demethylation index (CYP1A2 activity) compared with unaffected females (1.87 +/- 0.51 vs 1.47 +/- 0.27, P < 0.0005) and nonsmokers (1.69 +/- 0.23 vs 1.49 +/- 0.31, P < 0.02). Caffeine N1- and N7-demethylations indices were also lower among females (P < 0.0005) and nonsmokers (P < 0.02) who reported toxic symptoms. We conclude that CYP1A2 activity, gender and smoking are variables to be considered as influencing the toxicity of caffeine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8799528      PMCID: PMC2042629          DOI: 10.1046/j.1365-2125.1996.35418.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  22 in total

1.  Tacrine is not an ideal probe drug for measuring CYP1A2 activity in vivo.

Authors:  J T Larsen; L L Hansen; K Brosen
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

2.  Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes.

Authors:  Junling Yang; Minxia M He; Wei Niu; Steven A Wrighton; Li Li; Yang Liu; Chuan Li
Journal:  Br J Clin Pharmacol       Date:  2012-02       Impact factor: 4.335

3.  Evaluation of Tobacco Smoke and Diet as Sources of Exposure to Two Heterocyclic Aromatic Amines for the U.S. Population: NHANES 2013-2014.

Authors:  Li Zhang; Lanqing Wang; Yao Li; Yang Xia; Cindy M Chang; Baoyun Xia; Connie S Sosnoff; Brittany N Pine; B Rey deCastro; Benjamin C Blount
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-10-01       Impact factor: 4.254

Review 4.  Sex steroids and schizophrenia.

Authors:  Julie A Markham
Journal:  Rev Endocr Metab Disord       Date:  2012-09       Impact factor: 6.514

5.  Sequence variants at CYP1A1-CYP1A2 and AHR associate with coffee consumption.

Authors:  Patrick Sulem; Daniel F Gudbjartsson; Frank Geller; Inga Prokopenko; Bjarke Feenstra; Katja K H Aben; Barbara Franke; Martin den Heijer; Peter Kovacs; Michael Stumvoll; Reedik Mägi; Lisa R Yanek; Lewis C Becker; Heather A Boyd; Simon N Stacey; G Bragi Walters; Adalbjorg Jonasdottir; Gudmar Thorleifsson; Hilma Holm; Sigurjon A Gudjonsson; Thorunn Rafnar; Gyda Björnsdottir; Diane M Becker; Mads Melbye; Augustine Kong; Anke Tönjes; Thorgeir Thorgeirsson; Unnur Thorsteinsdottir; Lambertus A Kiemeney; Kari Stefansson
Journal:  Hum Mol Genet       Date:  2011-02-28       Impact factor: 6.150

Review 6.  Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective.

Authors:  H D Desai; J Seabolt; M W Jann
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 7.  Clinically significant pharmacokinetic interactions between dietary caffeine and medications.

Authors:  J A Carrillo; J Benitez
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

8.  Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population.

Authors:  D S Ou-Yang; S L Huang; W Wang; H G Xie; Z H Xu; Y Shu; H H Zhou
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

Review 9.  Mexiletine. A review of its therapeutic use in painful diabetic neuropathy.

Authors:  B Jarvis; A J Coukell
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

Review 10.  Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds.

Authors:  Guillermo Gervasini; Juan Antonio Carrillo; Julio Benitez
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.